Health Populi November 14, 2024
Jane Sarasohn-Kahn

For health care, there are many uncertainties as we reflect, one week after the 2024 U.S. elections, on probably policy and market impacts that we can expect in 2025 and beyond. In today’s Health Populi post, I’ll reflect on the first of several certainties we-know-we-know about U.S. health citizens and key factors shaping the American health ecosystem.

In this first of several posts on “What Stays True for U.S. Health Care Post #Election2024,” I’ll focus on U.S. consumer dissatisfaction with drug prices — across political party identification.

Let’s set the context with data from a recently-published study from Navitus Health Solutions exploring 2,000 U.S. insured consumers’ perspectives on prescription drug pricing and the role of PBMs (pharmacy benefit managers)....

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Patient / Consumer, Pharma, Pharma / Biotech
PBM reform dropped in Congress' funding package
Trump's Picks for Top Health Jobs Not Just Team of Rivals but 'Team of Opponents'
Telehealth gets short extension, physician pay is cut in spending bill
From Book Burnings to Data Deletions: Safeguarding Health Info in the Digital Age
Congressional spending plan: What’s in it for healthcare, and what isn’t

Share This Article